Respiratory Syncytial Virus (RSV) Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Respiratory Syncytial Virus (RSV) Therapeutics Market is projected to expand from a valuation of USD 2.25 billion in 2025 to USD 3.44 billion by 2031, reflecting a compound annual growth rate of 7.34%. This market encompasses a diverse array of pharmaceutical interventions, such as prophylactic vaccines, monoclonal antibodies, and antiviral drugs intended to manage or prevent infections caused by the respiratory syncytial virus. Key factors accelerating this growth trajectory include the rising incidence of severe respiratory ailments in susceptible pediatric and elderly groups, coupled with recent regulatory endorsements of new immunization products. Additionally, progress in rapid molecular diagnostic technologies is enabling quicker and more precise identification of infections, thereby broadening the patient base eligible for clinical treatment.

Despite these positive indicators, the sector faces substantial obstacles related to the widespread acceptance and effective deployment of these newly authorized treatments. Issues such as vaccine hesitancy and the logistical challenges associated with implementing immunization campaigns for adults frequently restrict market reach, leaving a significant segment of the intended population vulnerable. This utilization gap is underscored by recent data; the American Lung Association reported in 2024 that merely 24% of eligible seniors in the United States had been vaccinated against RSV, illustrating a sharp contrast between the availability of therapeutics and their actual preventive usage.

Market Drivers

The swift uptake of long-acting prophylactic monoclonal antibodies is fundamentally altering the Global Respiratory Syncytial Virus (RSV) Therapeutics Market, transitioning the focus from managing symptoms to actively preventing infection in pediatric groups. This shift is marked by the rapid incorporation of immunization agents, such as nirsevimab, into national health guidelines to meet significant needs within the infant population. The strong demand for these preventive options is reflected in their financial performance; Sanofi’s January 2025 press release on Q4 sales noted that Beyfortus generated €1.7 billion in 2024, attaining blockbuster status within its inaugural year. This commercial success aligns with improved clinical results, as the Centers for Disease Control and Prevention (CDC) reported in 2025 that RSV-related hospitalizations for infants under eight months dropped by 28% to 43% during the 2024-2025 season relative to pre-pandemic figures, highlighting the tangible benefits of widespread prophylaxis.

Another pivotal driver is the commercial launch of novel RSV vaccines and antivirals, which extends therapeutic options to susceptible older adults. This development encompasses the approval and distribution of protein subunit and mRNA vaccines, creating new revenue channels and establishing updated care standards for geriatric respiratory health. While the long-term outlook remains favorable, this segment currently faces instability as healthcare frameworks adjust usage protocols. For instance, a February 2025 BioPharma Dive article titled "GSK, Pfizer sales of RSV shots slow" indicated that GSK saw a 69% year-over-year drop in Arexvy sales during the fourth quarter following restricted age-based recommendations. Notwithstanding these temporary variations, the effective market introduction of these biological products continues to be a core component driving the sector’s overall growth and maturation.

Market Challenges

A major hurdle limiting the growth of the Global Respiratory Syncytial Virus (RSV) Therapeutics Market is the pronounced disconnect between regulatory authorization and broad patient acceptance. Although pharmaceutical entities have created effective immunization products, market progress stalls when these solutions fail to reach the target audience. This obstacle stems from persistent vaccine hesitancy and the logistical complexities of establishing adult immunization frameworks, which typically lack the robustness of pediatric systems. As a result, the commercial sustainability of these treatments is compromised, since poor adoption leads to diminished sales volumes and delayed returns on investment for manufacturers that have invested heavily in R&D.

The gap between the market's theoretical potential and its actual reach is highlighted by recent statistics on patient willingness. Data from the National Foundation for Infectious Diseases in 2024 reveals that only 21% of U.S. adults eligible for the RSV vaccine expressed a definite intention to receive it. This figure points to significant resistance within the target market, showing that despite the existence of preventive options, a large majority of the intended population remains unengaged. Until uptake levels correspond more closely with the availability of these products, the financial expansion of the RSV therapeutics industry will stay inhibited relative to its forecasted capabilities.

Market Trends

The uptake of maternal immunization for neonatal protection is creating a preventive route that operates separately from direct infant prophylaxis. By administering vaccines during pregnancy to convey passive immunity, this method effectively fills voids in pediatric healthcare provision. The commercial significance of this segment is growing due to focused distribution tactics aimed at prenatal care specialists. For example, a BioPharma Dive article from October 2024 titled "Pfizer sales of RSV vaccine ebb, but company gains market share" noted that Pfizer increased its shipments of Abrysvo to obstetricians and gynecologists by 56% in the first four weeks of the season relative to the prior year. This trend underscores the rising dependence on maternal vaccination as a vital tactic for ensuring neonatal well-being.

Concurrently, the incorporation of mRNA technology into RSV vaccine development is reshaping the competitive landscape by challenging traditional protein subunit approaches. This shift in technology enables the swift creation of scalable formulas, providing an efficient method to combat respiratory pathogens and paving the way for future combination vaccines. The practical arrival of this platform in the market is demonstrated by the launch of new mRNA products. In its "Third Quarter 2024 Financial Results" press release from November 2024, Moderna reported $10 million in net product sales for mRESVIA, establishing an initial revenue source for mRNA-based RSV therapeutics. This development marks a crucial move toward more flexible and quickly deployable vaccine solutions.

Key Players Profiled in the Respiratory Syncytial Virus (RSV) Therapeutics Market

• AbbVie, Inc.
• AstraZeneca PLC
• Bausch Health Companies Inc.
• F. Hoffmann-La Roche AG
• Gilead Sciences, Inc.
• GlaxoSmithKline PLC
• Merck & Co., Inc.
• ReViral Ltd.
• Teva Pharmaceutical Industries Ltd.
• Johnson & Johnson

Report Scope

In this report, the Global Respiratory Syncytial Virus (RSV) Therapeutics Market has been segmented into the following categories:

Respiratory Syncytial Virus (RSV) Therapeutics Market, by Type:

• Drug
• Vaccines

Respiratory Syncytial Virus (RSV) Therapeutics Market, by End User:

• Hospitals and Clinics
• Ambulatory Centers
• Others

Respiratory Syncytial Virus (RSV) Therapeutics Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Respiratory Syncytial Virus (RSV) Therapeutics Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.